TECVAYLI

Beyond's analysis on TECVAYLI

• 2026-09-23 — New clinical analysis suggests TECVAYLI and DARZALEX FASPRO combination could significantly enhance long-term survival for multiple myeloma patients

Recent news mentioning TECVAYLI

• 2026-09-23 — New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma

Appears alongside

• DARZALEX FASPRO

Browse the full archive →